Pamela R Lane

US Patent:

20010014458, Aug 16, 2001

Filed:

Mar 1, 2001

Appl. No.:

09/796965

Inventors:

Nabil Elshourbagy - West Chester PA, US
Pamela Lane - Norristown PA, US
Ping Tsui - Berwyn PA, US

International Classification:

A61K038/00
A61K031/70
A01N043/04
C12P021/06

US Classification:

435/007210, 435/006000, 435/069100, 514/012000, 514/044000

Abstract:

GPR6sb polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing GPR6sb polypeptides and polynucleotides in therapy, and diagnostic assays for such.

US Patent:

20010034331, Oct 25, 2001

Filed:

Jan 26, 2001

Appl. No.:

09/771063

Inventors:

Derk Bergsma - Berwyn PA, US
Nabil Elshourbagy - West Chester PA, US
Pamela Lane - Norristown PA, US
Xiaotong Li - Devon PA, US
Jeffrey Mooney - Limerick PA, US
Ping Tsui - Berwyn PA, US

International Classification:

A61K038/00
C07H021/04
A61K031/70
C12P021/06

US Classification:

514/044000, 435/006000, 435/069100, 514/012000, 536/023500

Abstract:

Human H218 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human H218 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

US Patent:

20020045214, Apr 18, 2002

Filed:

Mar 20, 2001

Appl. No.:

09/812272

Inventors:

Nabil Elshourbagy - West Chester PA, US
Pamela Lane - Norristown PA, US
Ping Tsui - Berwyn PA, US

International Classification:

C12P021/02
C12N005/06
C07K014/705
C07H021/04

US Classification:

435/069100, 435/325000, 530/350000, 536/023500

Abstract:

Rattus norvegus AXOR29 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize rattus norvegus AXOR29. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome.

US Patent:

20020045216, Apr 18, 2002

Filed:

Jun 12, 2001

Appl. No.:

09/879017

Inventors:

Nabil Elshourbagy - West Chester PA, US
Pamela Lane - Harleysville PA, US
Ping Tsui - Berwyn PA, US

International Classification:

C07K014/705
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/069100, 435/325000, 435/320100, 530/350000, 536/023500

Abstract:

Mus Musculus FMRL-3 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize Mus Musculus FMRL-3. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome.

US Patent:

20020061558, May 23, 2002

Filed:

Jun 12, 2001

Appl. No.:

09/879225

Inventors:

Nabil Elshourbagy - West Chester PA, US
Pamela Lane - Harleysville PA, US
Ping Tsui - Berwyn PA, US

International Classification:

C12P021/02
C12N005/06
C07H021/04
C07K014/705

US Classification:

435/069100, 435/325000, 435/320100, 530/350000, 536/023500

Abstract:

Mus musculus EDG7 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize Mus musculus EDG7. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome.

US Patent:

20020090691, Jul 11, 2002

Filed:

Jul 12, 2001

Appl. No.:

09/903799

Inventors:

Nabil Elshourbagy - West Chester PA, US
Pamela Lane - Harleysville PA, US
Ping Tsui - Berwyn PA, US

International Classification:

C12N009/00
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/183000, 435/325000, 435/320100, 435/069100, 536/023200

Abstract:

Mus musculus EDG4 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize Mus musculus EDG4. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome.

US Patent:

20040072227, Apr 15, 2004

Filed:

Jul 29, 2003

Appl. No.:

10/629952

Inventors:

Zdenka Jonak - Devon PA, US
Stephen Trulli - Havertown PA, US
Ping Tsui - Berwyn PA, US
Pamela Lane - Norristown PA, US

International Classification:

C12Q001/68
C07H021/04
C07K014/47

US Classification:

435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 536/023500

Abstract:

Human Mindin polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human Mindin polypeptides and polynucleotides in therapy, and diagnostic assays for such.

US Patent:

60430524, Mar 28, 2000

Filed:

Mar 4, 1998

Appl. No.:

9/034985

Inventors:

Pamela A Lane - Norristown PA
Ping Tsui - Berwyn PA
Nabil Elshourbagy - West Chester PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

C12D 1512
C07K 14705

US Classification:

435 691

Abstract:

GPR25 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing GPR25 polypeptides and polynucleotides in therapy, and diagnostic assays for such.